Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Palantir Stock Jumps After Strong Q4 Earnings Beat and Upbeat 2026 Revenue Forecast 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers 
Disney Board Nears CEO Decision as Josh D’Amaro Emerges as Leading Candidate 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
EAST RUTHERFORD, N.J., May 31, 2017 -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference on June 7, 2017 at 2:30 p.m. EDT in New York City.
The live audio webcast and slide presentation can be accessed from the Cambrex website at www.cambrex.com in the Investors section under “Webcasts & Presentations”, and a replay will be available for 90 days after the live event concludes.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com.
Contact: Stephanie LaFiura IR Associate Tel: +201 804 3037 Email: [email protected]
